UK’s National Institute for Clinical Excellence (NICE) To Re-evaluate GlaxoSmithKline’s Tyverb Cancer Drug

October 14, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LONDON (Reuters) - Britain's drug funding watchdog NICE said on Thursday patients taking GlaxoSmithKline's breast cancer pill Tyverb can continue with the drug while it assesses its use in advanced cases compared with Roche's Herceptin.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory Europe

GSK